Article PDF
Avoid common mistakes on your manuscript.
References
M Pirmohamed S James S Meakin et al. (2004) ArticleTitleAdverse drug reactions as a cause of admission to hospital: prospective analysis of 18820 patients. Br Med J 324 15–19
MT Martin C Codina M Tuset X Carné S Nogué J Ribas (2002) ArticleTitleProblemas relacionados con la medicación como causa del ingreso hospitalario. Med Clin (Barc) 118 205–210
JR Laporte X Carné X Vidal et al. (1991) ArticleTitleUpper gastrointestinal bleeding in relation to previous use of analgesic and non-steroidal anti-inflammatory drugs. Lancet 337 85–89 Occurrence Handle10.1016/0140-6736(91)90744-A Occurrence Handle1:STN:280:By6D1cjmvVY%3D Occurrence Handle1670734
MJS Langman J Weil P Wainwright et al. (1994) ArticleTitleRisks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 1075–1078 Occurrence Handle10.1016/S0140-6736(94)90185-6 Occurrence Handle1:STN:280:ByuB3M7gs1E%3D Occurrence Handle7909103
A Lanas E Bajador P Serrano et al. (2000) ArticleTitleNitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs and the risk of upper gastrointestinal bleeding. N Engl J Med 343 834–839
D Henry LL-Y Lim Rodríguez LA García et al. (1996) ArticleTitleVariability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312 1563–1566
S Hernández-Díaz LA García-Rodríguez (2000) ArticleTitleAssociation between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 160 2093–2099 Occurrence Handle10.1001/archinte.160.14.2093 Occurrence Handle1:STN:280:DC%2BD3czptVKgtQ%3D%3D Occurrence Handle10904451
JR Laporte L Ibañez X Vidal L Vendrell R Leone (2004) ArticleTitleUpper gastrointestinal bleeding associated with the use of NSAIDs. Drug Safety 27 411–420
GA FitzGerald C Patrono (2001) ArticleTitleThe coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 433–442 Occurrence Handle10.1056/NEJM200108093450607 Occurrence Handle1:STN:280:DC%2BD3MvltVyltQ%3D%3D Occurrence Handle11496855
GA FitzGerald (2004) ArticleTitleCoxibs and cardiovascular disease. N Engl J Med 351 1709–1711
EJ Topol (2004) ArticleTitleFailing the public health. Rofecoxib, Merck and the FDA. N Engl J Med 351 1707–1709
C Bombardier L Laine A Reicin et al. (2000) ArticleTitlefor the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 1520–1528 Occurrence Handle10.1056/NEJM200011233432103 Occurrence Handle1:CAS:528:DC%2BD3cXos1OhurY%3D Occurrence Handle11087881
ME Farkouh H Kirshner RA Harrington et al. (2004) ArticleTitleon behalf of the TARGRT Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcome: Randomised controlled trial. Lancet 364 675–684
MA Konstam MR Weir A Reicin et al. (2001) ArticleTitleCardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 102 2280–2288
E Rahme L Pilote J LeLorier (2002) ArticleTitleAssociation between naproxen use and protection against acute myocardial infraction. Arch Intern Med 162 1111–1115
DH Solomon RJ Glynn R Levin J Avorn (2002) ArticleTitleNonsteroidal anti-inflammatory drug use and acute myocardial infraction. Arch Intern Med 162 1099–1104
DJ Watson T Rhodes B Cai HA Guess (2002) ArticleTitleLower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162 1105–1110
DH Solomon S Schneeweiss RJ Glynn et al. (2003) ArticleTitleRelationship between selective cyclooxigenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 2068–2073
WB White G Faich JS Borer RW Makuch (2003) ArticleTitleCardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 92 411–418 Occurrence Handle10.1016/S0002-9149(03)00659-3 Occurrence Handle1:CAS:528:DC%2BD3sXmt1Kjs70%3D Occurrence Handle12914871
WB White G Faich A Whelton et al. (2002) ArticleTitleComparison of thromboembolic events in patients treated with celecoxib, a cyclooxigenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89 425–430 Occurrence Handle10.1016/S0002-9149(01)02265-2 Occurrence Handle1:CAS:528:DC%2BD38XhtVKlu78%3D Occurrence Handle11835924
F Oberholzer-Gee SN Inamdar (2004) ArticleTitleMerck’s recall of rofecoxib. A strategic perspective. N Engl J Med 351 2147–2149
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–2029.
Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364: 1995–1996.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carné, X., Cruz, N. Ten lessons to be learned from the withdrawal of Vioxx® (rofecoxib). Eur J Epidemiol 20, 127–129 (2005). https://doi.org/10.1007/s10654-004-6856-1
Issue Date:
DOI: https://doi.org/10.1007/s10654-004-6856-1